Method for preparing solid enrofloxacin nano particles

Abstract

The invention discloses a method for preparing solid enrofloxacin nano particles, which is characterized by comprising the following steps: firstly, preparing 1 percent aqueous solution of glacial acetic acid with distilled water, and adding chitosan into the aqueous solution under a condition of magnetic stirring to dissolve the chitosan and obtain 1.5 to 2.5mg / mL solution of chitosan; secondly, adding enrofloxacin raw material medicament into the solution of chitosan, continuing performing magnetic stirring for 10min to uniformly disperse the enrofloxacin raw material medicament, adjusting the pH value to 5.0 to obtain solution of enrofloxacin chitosan; thirdly, dissolving sodium tripolyphosphate in the distilled water to prepare 1.2 to 1.8mg / mL solution of sodium tripolyphosphate, slowly dripping the solution of sodium tripolyphosphate into the solution of enrofloxacin chitosan under the condition of magnetic stirring, after dripping is finished, continuing performing magnetic stirring for 1h, immobilizing to obtain enrofloxacin chitosan nano particle suspension; and finally, filling the immobilized enrofloxacin chitosan nano particle suspension into frozen bottles, pre-freezing the bottles for 2h at the temperature of 70 DEG C below zero, vacuumizing and freeze-drying the bottles at the temperature of 50 DEG C below zero to obtain the solid enrofloxacin nano particles.

Description

Technical field: [0001] The invention belongs to the technical field of aquatic pharmaceutical preparations, and in particular relates to a preparation method of solid enrofloxacin nanoparticles. Background technique: [0002] Enrofloxacin (ENR), also known as ethyl ciprofloxacin, was approved by the US FDA in 1996. It is a third-generation fluoroquinolone antimicrobial drug dedicated to poultry, livestock and aquatic products, which can be achieved by inhibiting bacterial DNA helicase. The antibacterial effect has the characteristics of broad bactericidal spectrum, wide distribution in the body, and no cross-resistance with other drugs. [0003] At present, enrofloxacin still adopts the first and second-generation traditional dosage forms represented by powder in production, which generally have disadvantages such as low bioavailability, short drug effect period, large gastrointestinal irritation, and easy drug resistance. Poor stress resistance, easy to be degraded by lig...

AI Technical Summary

Problems solved by technology

[0003] At present, enrofloxacin still adopts the first and second-generation traditional dosage forms represented by powder in production, which generally have disadvantages such as low bioavailability, short drug effect period, large gastrointestinal irritation, and easy drug resistance. Poor stress resistance, easy to be degraded by light and heat reactions in the process of drug production, transportation, storage, etc., leading to problems such as low drug efficacy, increased dosage, and prolonged treatment cycle during the treatment process, thus indirectly causing safety hazards of aquatic products such as drug residues

[0004] Although there have been some relevant studies on chitosan as a carrier in China, they are all limited to the preparation and evaluation of nanoparticle suspensions, and cannot provide an effective solution for the production and application of this dosage form.

Images